Efficacy and safety of the Bushen Tiaochong recipe combined with alendronate sodium for the treatment of postmenopausal senile degenerative osteoporosis: study protocol for a randomized controlled trial

doi:10.3969/j.issn.2095-4344.0134

Abstract

Abstract:

BACKGROUND: Alendronate sodium is a commonly used western medicine for the treatment of osteoporosis, but it has many adverse reactions. The main component of the traditional Chinese medicine, known as the Bushen Tiaochong recipe, is Epimedium brevicornu Maxim. (epimedium). Pharmacological studies have shown that the main active ingredient of Epimedium is icariin. Icariin has an estrogen-like effect, can prevent against bone loss and improve bone strength, and has a definite effect on the treatment of postmenopausal senile degenerative osteoporosis.
OBJECTIVE: To testify the hypothesis that the Bushen Tiaochong recipe combined with alendronate sodium will be more effective, as well as safer and more reliable than alendronate sodium alone for the treatment of postmenopausal senile degenerative osteoporosis.
METHODS: Two hundred patients with postmenopausal senile degenerative osteoporosis will be randomly assigned to an observation group and a control group. In the control group, patients will be given alendronate sodium tablets 10 mg/d and calcium carbonate D3 chewable tablets 0.6 g/d. In the observation group, patients will receive the same treatment as the control group and the Bushen Tiaochong recipe, simmering, twice per day (once in the morning and once in the evening). The duration of treatment will be 6 months in both groups. The primary outcome measure is the overall efficacy 6 months after treatment in both groups. The secondary outcome measures are Visual Analogue Scale scores for waist and back pain; lumbar spine (L2–4) bone mineral density; serum levels of calcium, phosphorus, alkaline phosphatase, osteocalcin, estradiol, follicle stimulating hormone, luteinizing hormone, interleukin-1, and interleukin-6 before and 6 months after treatment; and incidence of adverse reactions 6 months after treatment. This trial has been approved by the Ethics Committee of the Affiliated Hospital of Qinghai University of China (approval number: QHY1703F). The study protocol will be conducted in accordance with the Declaration of Helsinki, formulated by the World Medical Association. Written informed consent will be obtained from all participants. The recruitment of subjects will begin in January 2018. Samples and data will be collected from January to December 2018. Outcome measures will be analyzed in March 2019. This trial will be completed in April 2019. The results of the trial will be reported in a scientific conference or disseminated in a peer-reviewed journal. This trial was registered with the Chinese Clinical Trial Registry (registration number: ChiCTR-ONC-17013947).
DISCUSSION: We hope to verify that the Bushen Tiaochong recipe combined with alendronate sodium provides better results than alendronate sodium alone for the treatment of postmenopausal senile degenerative osteoporosis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Tissue Engineering, Osteoporosis, Alkaline Phosphatase

CLC Number:

R318

Qi Mei-ge, Qi Lin, Li Li, Song Jing. Efficacy and safety of the Bushen Tiaochong recipe combined with alendronate sodium for the treatment of postmenopausal senile degenerative osteoporosis: study protocol for a randomized controlled trial[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(8): 1173-1177.

Figures/Tables 1

References

[1] Njeze Ngozi R, Ikechukwu O, Miriam A, et al. Awareness of osteoporosis in a polytechnic in Enugu, South East Nigeria. Arch Osteoporos. 2017 doi: 10.1007/s11657-017-0342-3.

[2] Zhang H, Yue H, Wang C, et al. Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta. Mol Med Rep. 2016;14:4918-4926.

[3] Xie L, Ding F, Jiao J, et al. Total Hip and Knee arthroplasty in a patient with osteopetrosis: a case report and review of the literature. BMC Musculoskelet Disord. 2015;16:259.

[4] Liu W, Yang LH, Kong XC, et al. Meta-analysis of osteoporosis: fracture risks, medication and treatment. Minerva Med. 2015;106:203-214.

[5] Khadilkar AV, Mandlik RM. Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health. 2015;7:841-850.

[6] Pazhekattu R, Lau AN, Adachi JD. The tissue-selective estrogen complex: a review of current evidence. Rheumatol Ther. 2015;2:47-58.

[7] Rosales-Aujang E, Muñoz-Enciso JM, Arias-Ulloa R. Prevalence of osteopenia and osteoporosis in postmenopausal women and its relation to risk factors. Ginecol Obstet Mex. 2014;82:223-228.

[8] Doria C, Leali PT, Solla F, et al. Denosumab is really effective in the treatment of osteoporosis secondary to hypogonadism in prostate carcinoma patients? A prospective randomized multicenter international study. Clin Cases Miner Bone Metab. 2016;13(3):195-199.

[9] Bae J, Park JW. Preparation of an injectable depot system for long-term delivery of alendronate and evaluation of its anti-osteoporotic effect in an ovariectomized rat model. Int J Pharm. 2015;480:37-47.

[10] Minciullo PL, Allegra A, D'Angelo A, et al. Challenge test to bisphosphonates in patients with hypersensitivity reactions to drugs. Allergol Immunopathol (Madr). 2015;43:127-130.

[11] McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-420.

[12] 谢雁鸣,宇文亚,董福慧,等.原发性骨质疏松症中医临床实践指南(摘录)[J].中华中医药杂志,2012,27(7):1886-1890.

[13] Xu JH, Yao M, Ye J, et al. One mass improved effect of icariin for postmenopausal osteoporosis in ovariectomy-induced rats: a meta-analysis and systematic review. Menopause. 2016; 23(10):1152-1157.

[14] Luo Z, Liu M, Sun L, et al. Icariin recovers the osteogenic differentiation and bone formation of bone marrow stromal cells from a rat model of estrogen deficiency-induced osteoporosis. Mol Med Rep. 2015;12:382-388.

[15] 中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1): 2-18.

[16] 刘保新.《中药新药临床研究指导原则》与绝经后骨质疏松症的辨证论治[J].中国美容医学杂志,2010,19(s3):135-138.

[17] 高慧,夏天,韩冰,等.中药补肾调冲方治疗卵巢早衰的临床研究[J].辽宁中医杂志,2007,34(11):1557-1560.

[18] Knop C, Oeser M, Bastian L, et al. Development and validation of the Visual Analogue Scale (VAS) Spine Score. Unfallchirurg. 2011;104:488-497.

[19] 唐保明.补肾调冲方治疗绝经后骨质疏松症62例[J].中国实验方剂学杂志,2015,21(6):191-194.

[20] Liu GB, Zhang GP, Ren QY, et al. Classification of ankle injury on radiography and magnetic resonance imaging: study protocol for a retrospective, self-controlled, clinical trial with 3-month followup. Clin Transl Orthop. 2016;1:170-176.

[21] Chen Y, Qu S, Ma G, et al. Femoral nerve block prevents deep venous thrombosis of the lower extremity after knee arthroplasty: a single-center randomized controlled trial. Clin Transl Orthop. 2016;1:1-5.

[22] Venugopal Y, Hatta SFWM, Musa N, et al. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics. Asia Pac J Clin Nutr. 2017;26(3):412-420.

[23] Tan W, Sun J, Zhou L, et al. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis. J Clin Pharm Ther. 2016;41(5):519-523.

[24] Wu YC, Xu J, Yang L, et al. The effect of low-frequency pulsed electromagnetic fields on balance ability of patients with post-menopausal osteoporosis. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45(1):116-119.

[25] Bock O, Börst H, Beller G, et al. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT. Bone. 2012;50(1):317-324.

[26] Fernández-García D, Muñoz-Torres M, Mezquita-Raya P, et al. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest. 2008;31(5):416-421.

[27] Deane A, Constancio L, Fogelman I, et al. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord. 2007;8:3.

[28] Maugeri D, Mamazza C, Lo Giudice F, et al. Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis. Arch Gerontol Geriatr. 2005; 40(3):299-305.

[29] Sarli M, Fradinger E, Morillo S, et al. Treatment of post menopausal osteoporosis with intravenous pamidronate in patients with esophagogastric pathology. Medicina (B Aires). 1998;58(5 Pt 1):446-452.